Report Description of the EU Drug Addiction Market Analysis

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for EU Drug Addiction Market Analysis


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the EU Drug Addiction Market Analysis


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy based consulting analysis

EU Drug Addiction Market Analysis Executive Summary

Europe is confronted with a rapidly evolving drug market. The increased potency and purity of illicit drugs, the record numbers of seizures and increased production in the EU, all indicate that the availability of illicit substances is growing. We also see a dramatic increase in the number of new, and often highly potent, synthetic substances present on the market.

Market Size and Key Findings

The EU Drug Addiction Market Analysis size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The EU drug market was conservatively estimated to be worth about EUR 30 billion in 2017. Cannabis accounts for about two fifths of this total (39 %), cocaine (31 %), heroin (25 %) and amphetamines and MDMA (5 %).



Market Dynamics

Market Growth Drivers Analysis

The drug market is a major source of income for organised crime groups (OCGs) in the EU, with minimum estimated retail value of EUR 30 billion per year. In addition to the economic impact, drug-related deaths and other harms to public health, there are broader consequences of drug markets, such as links with wider criminal activities and terrorism; the negative impact on the legal economy; violence in communities; damage to the environment; and the increasingly important issue of how the drug market can fuel corruption and undermine governance. The drug market is becoming more globally connected and technologically enabled. The main drivers of change behind the developments and new threats detailed in this report stem from the ability of OCGs to exploit the opportunities arising from the existence of global commercial markets and the associated logistical developments and digitalisation.

Market Restraints

Drug market-related violence and intimidation is a growing concern in the EU. Some new models of supply have emerged that are associated with high levels of violence and exploitation. There is no systematic assessment of violent crime associated with the operation of the drug market. However, new data on drug-related homicides suggest it is a significant phenomenon in some countries and more likely to involve the use of firearms than other types of homicide. The violence and intimidation associated with the drug markets spills over and affects families and neighborhoods as well as the individuals directly involved. The illegal financial flows have impacts on the legal economy in many ways, such as when businesses and high-value assets are acquired to launder cash.

COVID-19 impact on "EU Drug Addiction Market Analysis

The ongoing COVID-19 pandemic is likely to have an impact on the lives of people who use drugs and on the services responding to their needs owing to both restrictive measures introduced to mitigate the spread of the virus and any accompanying economic downturn (Costa Storti et al., 2021). In 2020, the gross domestic product of the EU fell by 7.4 % and a further negative impact on EU economies is expected in 2021. It has been suggested that the most vulnerable will suffer disproportionately from the COVID-19 economic recession (OECD, 2020).

Competitive Landscape

Key Players

Key participants include Pfizer, Indivior, Novartis, Alkermes, Cipla, Mylan, Dr. Reddy\'s Laboratorie, Glenmark, PLIVA (Odyssey), and Teva Pharmaceutical, among others.

In November 2018, Sandoz, a mentionable market player, along with Pear Therapeutics had announced the launch of reSET, which focuses on the treatment of patients with Substance Use Disorder. It is the only and the first FDA-authorized prescription digital therapeutics for treating the condition. Thus, such initiatives by market players are not only contributing to increasing the market share of these companies, but it also helps in boosting the overall market growth.

Products in Pipeline

The main source countries, where new psychoactive substances (NPS) are sold openly by chemical and pharmaceutical companies, are China and, to a lesser extent but particularly for those sold as medicines, India. However, a small number of illicit laboratories have also been detected in EU countries, such as the Netherlands and Poland, usually producing synthetic cathinones. Interactions between the NPS market and the market in established controlled drugs have become stronger, with NPS increasingly sold alongside illicit substances or in mixtures with them. Overlaps also exist with the market for fake medicines.

Notable Recent Deals

• Pfizer, one of the mentionable market players, has been working in collaboration with Eli Lilly and Co. for developing non-opioid chronic pain medication called tanezumab. On 13th June 2017, this collaboration got a major boost when the drug won fast-track designation from the Food and Drug Administration for treating chronic back pain and osteoarthritis. Such initiatives by the market would not only positively impact their market position, but it would boost the overall growth of the market.


• In October 2017, Maryland Addiction Recovery Center of Towson and Caron Treatment Centers made an announcement about the commencement of a new joint venture between the enterprises and the purchase of Encore Recovery Solutions based in Arlington, Virginia.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario

A number of themes that have important implications for EU policies and actions recur across the analysis presented in this report. The contemporary drug market is increasingly complex, adaptive and dynamic; it is also more global in nature and more interlinked than in the past. EU policies and responses need to be equally agile, adaptive and joined-up if they are to effectively address current and future challenges in this area. In addition to operational activities, it is important that full use is made of the range of policy tools available: these include coordination mechanisms and strategies, bilateral engagement with third countries and industry, and the use of legislative and financial instruments.